Conferences Participant Highlights from AAAAI 2021 Among the specific topics commanding healthcare professionals' (HCP) attention were the potential for Sanofi’s Dupixent in eosinophilic esophagitis, Amgen’s tezepelumab in uncontrolled asthma, and Lilly’s Olumiant in atopic dermatitis.
Research Dermatologists and Rheumatologists Weigh In on Immunology Needs and Shifts in 2021 Across multiple indications, physicians anticipate 2021 will be an exciting year for advancing treatments across autoimmune and auto-inflammatory conditions. In a study conducted by ZoomRx late December 2020, 107 practicing U.S. rheumatologists
